Dicot

In order to create more awareness of Dicot and the research on its potency drug candidate globally, the company now intends to intensify its internationalization work. Primarily, the goal is to reach representatives within the industry and international investors as well as to fulfill the long-term clinical and regulatory drug development plan in relation to authority requirements from an international perspective. The funds granted from the governmental business developer Almi equivalent to €22,000, is earmarked to support these activities.

“Shortly we plan to start clinical studies. Due to this, it is good timing for us to intensify the internationalization of the company as we operate on a global market. Almi's support means a lot in this endeavor and is a recognition of Dicot as a growth company," says Elin Trampe, Dicot's CEO.

For further information, please contact:

Elin Trampe, CEO

Phone: +46 739 80 14 08

E-mail: elin.trampe@dicot.se 

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market. 

Dicot is listed on Spotlight Stock Market and has approximately 4,100 shareholders. For more information, please visit www.dicot.se.